← All Jazz Pharmaceuticals PLC filings

Jazz Pharmaceuticals PLC 8-K filings

NASDAQ
JAZZ
Jazz Pharmaceuticals PLC
8-K: Jazz Pharmaceuticals Refinances $2.7 Billion Term Loan, Secures Lower Interest Rate
Jazz Pharmaceuticals has successfully repriced its existing U.S. dollar term loan, converting it to a new tranche with a reduced interest rate margin.
NASDAQ
JAZZ
Jazz Pharmaceuticals PLC
8-K: Jazz Pharmaceuticals Director Catherine Sohn Announces Retirement
Catherine Sohn, a director at Jazz Pharmaceuticals, has announced her retirement and will not seek re-election at the company's 2024 annual general meeting.
NASDAQ
JAZZ
Jazz Pharmaceuticals PLC
8-K: Jazz Pharmaceuticals Reports 12% Revenue Growth in Q1 2024, Affirms Full-Year Guidance
Jazz Pharmaceuticals announced a 12% year-over-year revenue increase driven by key products and affirmed its 2024 financial guidance.
NASDAQ
JAZZ
Jazz Pharmaceuticals PLC
8-K: Jazz Pharmaceuticals Reports Strong 2023 Results and Provides Optimistic 2024 Guidance
Jazz Pharmaceuticals announced robust full-year and fourth-quarter 2023 financial results, highlighted by significant revenue growth and provided a positive financial outlook for 2024.
NASDAQ
JAZZ
Jazz Pharmaceuticals PLC
8-K: Jazz Pharmaceuticals Appoints New Director and Announces Board Resignation
Jazz Pharmaceuticals has appointed Patrick Kennedy to its board of directors, effective March 1, 2024, while Peter Gray will not seek re-election at the 2024 annual meeting.
NASDAQ
JAZZ
Jazz Pharmaceuticals PLC
8-K: Jazz Pharmaceuticals Appoints Philip Johnson as New Chief Financial Officer
Jazz Pharmaceuticals has appointed Philip Johnson as its new Executive Vice President and Chief Financial Officer, effective March 1, 2024.
NASDAQ
JAZZ
Jazz Pharmaceuticals PLC
8-K: Jazz Pharmaceuticals Refinances $2.7 Billion in Term Loans, Securing Lower Interest Rates
Jazz Pharmaceuticals has successfully repriced its existing U.S. dollar term loans, resulting in a reduction of the applicable interest rate margin.